Core Laboratories NV (CLB)
Official siteENERGY • OIL & GAS EQUIPMENT & SERVICES • NYSE
Market Cap: $417.45M
Last updated: Nov 17, 2026 at 11:04 AM ET
Core Laboratories NV (CLB) Stock Forecast
Analysts expect Core Laboratories NV (CLB) to earn $0.51 per share in the fiscal year ending Dec 31, 2026, on revenue of $511.86M. Of 3 analysts, 2 rate the stock Buy or Strong Buy, 0 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 2.67, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 67% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 33.3% |
| Buy | 1 | 33.3% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 33.3% |
- Consensus
- Hold
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 35.3% and revenue estimates rise 2.5%.
- Fiscal year ending Dec 31, 2026
- $0.51
- EPS consensus, revenue $511.86M
- Fiscal year ending Dec 31, 2027
- $0.69
- EPS consensus, revenue $524.76M
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.51 | $0.49 to $0.52 | 3 | $511.86M | $508.70M to $515.50M | 3 |
| Dec 31, 2027 | $0.69 | $0.54 to $0.79 | 3 | $524.76M | $507.90M to $540.67M | 3 |
Quarterly Estimates
The EPS consensus falls from $0.17 for the quarter ending Dec 31, 2026 to $0.13 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.17 | $0.15 to $0.20 | 4 | $134.65M | $127.89M to $143.33M | 4 |
| Mar 31, 2027 | $0.13 | $0.13 to $0.13 | 1 | $127.90M | $127.90M to $127.90M | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 5.6% from $0.54.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.51 | $0.46 | $0.46 | $0.43 | $0.54 | -6.2% |
| Fiscal year ending Dec 31, 2027 | $0.69 | $0.70 | $0.70 | $0.68 | $0.86 | -19.3% |
Frequently Asked Questions About CLB
What is the CLB stock forecast?
Consensus analyst estimates put Core Laboratories NV's EPS at $0.51 for the fiscal year ending Dec 31, 2026, on revenue of $511.86M. The consensus rating from 3 analysts is Hold.
How do analysts rate CLB stock?
Of 3 analysts covering Core Laboratories NV, 1 rates it Strong Buy, 1 Buy, 0 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from CLB next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.51, with estimates from $0.49 to $0.52 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.69, with estimates from $0.54 to $0.79 from 3 analysts.
What revenue do analysts expect from Core Laboratories NV next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $511.86M, with estimates from $508.70M to $515.50M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $524.76M, with estimates from $507.90M to $540.67M.
How many analysts cover CLB?
3 analysts rate Core Laboratories NV stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CLB pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors